Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C15H15FN4O |
| Molecular Weight | 286.3042 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1N=C(C)C2=C1N(C)C(=O)CN=C2C3=CC=CC=C3F
InChI
InChIKey=GDSCFOSHSOWNDL-UHFFFAOYSA-N
InChI=1S/C15H15FN4O/c1-9-13-14(10-6-4-5-7-11(10)16)17-8-12(21)19(2)15(13)20(3)18-9/h4-7H,8H2,1-3H3
| Molecular Formula | C15H15FN4O |
| Molecular Weight | 286.3042 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Zolazepam is used as an anaesthetic in veterinary medicine. Zolazepam is usually administered in combination with other drugs such as the NMDA antagonist tiletamine. This combination is indicated in cats for restraint or for anesthesia combined with muscle relaxation and in dogs for restraint and minor procedures of short duration requiring mild to moderate analgesia. Used alone, tiletamine does not provide adequate muscle relaxation for abdominal surgical procedures. When combined with zolazepam hydrochloride, good muscle relaxation is generally attained during the phase of deep surgical anesthesia.
Approval Year
Doses
| Dose | Population | Adverse events |
|---|---|---|
100 mg single, intravenous Abused dose Dose: 100 mg Route: intravenous Route: single Dose: 100 mg Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
Disc. AE: Syncopal attack... AEs leading to discontinuation/dose reduction: Syncopal attack Sources: |
1125 mg single, intravenous Abused dose Dose: 1125 mg Route: intravenous Route: single Dose: 1125 mg Sources: |
unknown, ADULT Health Status: unknown Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
Disc. AE: Tremor, Lethargy... AEs leading to discontinuation/dose reduction: Tremor Sources: Lethargy Vision blurred Salivation Chills Fatigue |
875 mg single, oral Abused dose |
unknown, ADULT Health Status: unknown Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
Disc. AE: Stupor, Hypertension... AEs leading to discontinuation/dose reduction: Stupor Sources: Hypertension Bradycardia Mental confusion |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Syncopal attack | Disc. AE | 100 mg single, intravenous Abused dose Dose: 100 mg Route: intravenous Route: single Dose: 100 mg Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
| Chills | Disc. AE | 1125 mg single, intravenous Abused dose Dose: 1125 mg Route: intravenous Route: single Dose: 1125 mg Sources: |
unknown, ADULT Health Status: unknown Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
| Fatigue | Disc. AE | 1125 mg single, intravenous Abused dose Dose: 1125 mg Route: intravenous Route: single Dose: 1125 mg Sources: |
unknown, ADULT Health Status: unknown Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
| Lethargy | Disc. AE | 1125 mg single, intravenous Abused dose Dose: 1125 mg Route: intravenous Route: single Dose: 1125 mg Sources: |
unknown, ADULT Health Status: unknown Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
| Salivation | Disc. AE | 1125 mg single, intravenous Abused dose Dose: 1125 mg Route: intravenous Route: single Dose: 1125 mg Sources: |
unknown, ADULT Health Status: unknown Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
| Tremor | Disc. AE | 1125 mg single, intravenous Abused dose Dose: 1125 mg Route: intravenous Route: single Dose: 1125 mg Sources: |
unknown, ADULT Health Status: unknown Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
| Vision blurred | Disc. AE | 1125 mg single, intravenous Abused dose Dose: 1125 mg Route: intravenous Route: single Dose: 1125 mg Sources: |
unknown, ADULT Health Status: unknown Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
| Bradycardia | Disc. AE | 875 mg single, oral Abused dose |
unknown, ADULT Health Status: unknown Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
| Hypertension | Disc. AE | 875 mg single, oral Abused dose |
unknown, ADULT Health Status: unknown Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
| Mental confusion | Disc. AE | 875 mg single, oral Abused dose |
unknown, ADULT Health Status: unknown Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
| Stupor | Disc. AE | 875 mg single, oral Abused dose |
unknown, ADULT Health Status: unknown Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Evaluation of anesthetic protocol for the collection of semen from captive collared peccaries (Tayassu tajacu) by electroejaculation. | 2009-12 |
|
| Effects of different general anesthetics on serum hemolysis and hepatic and muscular glycogenolysis in rats. | 2009-11 |
|
| The effect of amnion-derived cellular cytokine solution on the epithelialization of partial-thickness donor site wounds in normal and streptozotocin-induced diabetic swine. | 2009-10-20 |
|
| Movement disorder caused by abuse of veterinary anesthesia containing tiletamine. | 2009-10 |
|
| A serological survey of infectious disease in Yellowstone National Park's canid community. | 2009-09-16 |
|
| Efficacy of strain RB51 vaccine in protecting infection and vertical transmission against Brucella abortus in Sprague-Dawley rats. | 2009-09 |
|
| Evaluation of three immobilization combinations in the capybara (Hydrochoerus hydrochaeris). | 2009-08-01 |
|
| In vivo properties of the proangiogenic peptide QK. | 2009-06-08 |
|
| The effects of different anesthetic agents on short electroretinography protocol in dogs. | 2009-06 |
|
| Imaging evaluation of the liver using multi-detector row computed tomography in micropigs as potential living liver donors. | 2009-06 |
|
| Use of two anesthetic combinations for semen collection by electroejaculation from captive coatis (Nasua nasua). | 2009-05 |
|
| A pig model of acute Staphylococcus aureus induced pyemia. | 2009-03-27 |
|
| Comparison of azaperone-detomidine-butorphanol-ketamine and azaperone-tiletamine-zolazepam for anaesthesia in piglets. | 2009-03 |
|
| Biliary clearance of bromosulfophthalein in anesthetized and freely moving conscious rat. | 2009-03 |
|
| Urinary cortisol responses to unusual events in captive chimpanzees (Pan troglodytes). | 2009-01 |
|
| Insulin reduces cerebral ischemia/reperfusion injury in the hippocampus of diabetic rats: a role for glycogen synthase kinase-3beta. | 2009-01 |
|
| A recruitment breath manoeuvre directly after endotracheal suction improves lung function: an experimental study in pigs. | 2009 |
|
| Physiological effects of the TASER C2 conducted energy weapon. | 2009 |
|
| Acute effects of an alternative electronic-control-device waveform in swine. | 2009 |
|
| Reversible immobilization of asiatic black bear (Ursus thibetanus) with detomidine-tiletamine-zolazepam and atipamezole. | 2008-12 |
|
| Effects of premedication with tiletamine/zolazepam/medetomidine during general anesthesia using sevoflurane/fentanyl in swine undergoing pancreas transplantation. | 2008-11 |
|
| Methods of advanced wound management for care of combined traumatic and chemical warfare injuries. | 2008-07-21 |
|
| Principal component analysis for the comparison of metabolic profiles from human rectal cancer biopsies and colorectal xenografts using high-resolution magic angle spinning 1H magnetic resonance spectroscopy. | 2008-04-25 |
|
| Biomedical evaluation of free-ranging red ruffed lemurs (Varecia rubra) within the Masoala National Park, Madagascar. | 2008-03 |
|
| Clinical and pathologic features of cynomolgus macaques (Macaca fascicularis) infected with aerosolized Yersinia pestis. | 2008-02 |
|
| Effects of acepromazine and butorphanol on tiletamine-zolazepam anesthesia in llamas. | 2008-02 |
|
| Effects of two different anaesthetics on serum concentrations of cortisol and luteinizing hormone in barrows and gilts. | 2008-01 |
|
| Changes in minimal alveolar concentration of isoflurane following treatment with medetomidine and tiletamine/zolazepam, epidural morphine or systemic buprenorphine in pigs. | 2008-01 |
|
| Echocardiographic reference ranges for sedated healthy cynomolgus monkeys (Macaca fascicularis). | 2008-01 |
|
| Antagonistic effects of yohimbine in pigs anaesthetised with tiletamine/zolazepam and xylazine. | 2007-11-03 |
|
| Tiletamine-zolazepam and xylazine is a potent cardiodepressive combination: a case report. | 2007-11 |
|
| Nitric oxide and angiotensin II receptors mediate the pressor effect of angiotensin II: a study in conscious and zoletil-anesthetized rats. | 2007-11 |
|
| Serial CT findings of Paragonimus infested dogs and the Micro-CT findings of the worm cysts. | 2007-10-10 |
|
| Cavo-portal transposition in rat: a new simple model. | 2007-08-16 |
|
| Pseudomyxoma peritonei--two novel orthotopic mouse models portray the PMCA-I histopathologic subtype. | 2007-06-30 |
|
| Effects of tiletamine-zolazepam anaesthesia on plasma antioxidative status and some haematological parameters in sheep. | 2007-06 |
|
| Tiletamine-zolazepam-xylazine immobilization of fishers (Martes pennanti). | 2007-04 |
|
| Immobilization of Japanese black bears (Ursus thibetanus japonicus) with tiletamine hydrochloride and zolazepam hydrochloride. | 2007-04 |
|
| Comparison of cardiovascular effects of tiletamine-zolazepam, pentobarbital, and ketamine-xylazine in male rats. | 2007-03 |
|
| A comparison of anesthetic and cardiorespiratory effects of tiletamine-zolazepam-butorphanol and tiletamine-zolazepam-butorphanol- medetomidine in cats. | 2007 |
|
| Comparison of anesthetic and cardiorespiratory effects of tiletamine-zolazepam-butorphanol and tiletamine-zolazepam-butorphanol-medetomidine in dogs. | 2007 |
|
| Cardiopulmonary effects of medetomidine or midazolam in combination with ketamine or tiletamine/zolazepam for the immobilisation of captive cheetahs (Acinonyx jubatus). | 2006-12 |
|
| Reversible anesthesia of Southeast Asian primates with medetomidine, zolazepam, and tiletamine. | 2006-12 |
|
| Pharmacokinetics of tiletamine and zolazepam (Telazol) in anesthetized pigs. | 2006-12 |
|
| Determination of constituents of Telazol--tiletamine and zolazepam by a gas chromatography/mass spectrometry-based method. | 2006-10-02 |
|
| Reversible immobilization of free-ranging African lions (Panthera leo) with medetomidine-tiletamine-zolazepam and atipamezole. | 2006-04 |
|
| Immobilization of free-ranging maned wolf (Chrysocyon brachyurus) with tiletamine and zolazepam in central Brazil. | 2006-03 |
|
| Chemical immobilization of adult female Weddell seals with tiletamine and zolazepam: effects of age, condition and stage of lactation. | 2006-02-09 |
|
| Clinical and cardiorespiratory effects of propofol in the spotted bamboo shark (Chylloscyllium plagiosum). | 2005-12 |
|
| Reversible anaesthesia of free-ranging lions (Panthera leo) in Zimbabwe. | 2005-12 |
Patents
Sample Use Guides
Dogs: In healthy dogs, an initial intramuscular dosage of 3 to 4.5 mg/lb (6.6 to 9.9 mg/kg) TELAZOL ((tiletamine HCl and zolazepam HCl) is recommended for diagnostic purposes; 4.5 to 6 mg/lb (9.9 to 13.2 mg/kg) for minor procedures of short duration, such as treatment of lacerations and wounds, castrations and other procedures requiring mild to moderate analgesia. When supplemental doses of TELAZOL are required, such individual supplemental doses should be less than the initial dose, and the total dose given (initial dose plus supplemental dose or doses) should not exceed 12 mg/lb (26.4 mg/kg). The maximum safe dose is 13.6 mg/lb (29.92 mg/kg).
Cats: In healthy cats, an initial TELAZOL dosage of 4.4 to 5.4 mg/lb (9.7 to 11.9 mg/kg) is recommended for such procedures as dentistry, treatment of abscesses, foreign body removal and related types of surgery; 4.8 to 5.7 mg/lb (10.6 to 12.5 mg/kg) for minor procedures requiring mild to moderate analgesia, such as repair of lacerations, castrations and other procedures of short duration. Initial dosages of 6.5 to 7.2 mg/lb (14.3 to 15.8 mg/kg) are recommended for ovario- hysterectomy and onychectomy. When supplemental doses of TELAZOL are required, such individual supplemental doses should be given in increments that are less than the initial dose, and the total dose given (initial dose plus supplemental doses) should not exceed the maximum allowable safe dose of 32.7 mg/lb (72 mg/kg).
Route of Administration:
Intramuscular
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:26:21 GMT 2025
by
admin
on
Mon Mar 31 18:26:21 GMT 2025
|
| Record UNII |
G1R474U58U
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C1012
Created by
admin on Mon Mar 31 18:26:21 GMT 2025 , Edited by admin on Mon Mar 31 18:26:21 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
G1R474U58U
Created by
admin on Mon Mar 31 18:26:21 GMT 2025 , Edited by admin on Mon Mar 31 18:26:21 GMT 2025
|
PRIMARY | |||
|
C84252
Created by
admin on Mon Mar 31 18:26:21 GMT 2025 , Edited by admin on Mon Mar 31 18:26:21 GMT 2025
|
PRIMARY | |||
|
DB11555
Created by
admin on Mon Mar 31 18:26:21 GMT 2025 , Edited by admin on Mon Mar 31 18:26:21 GMT 2025
|
PRIMARY | |||
|
DTXSID30185278
Created by
admin on Mon Mar 31 18:26:21 GMT 2025 , Edited by admin on Mon Mar 31 18:26:21 GMT 2025
|
PRIMARY | |||
|
CHEMBL2111144
Created by
admin on Mon Mar 31 18:26:21 GMT 2025 , Edited by admin on Mon Mar 31 18:26:21 GMT 2025
|
PRIMARY | |||
|
35775
Created by
admin on Mon Mar 31 18:26:21 GMT 2025 , Edited by admin on Mon Mar 31 18:26:21 GMT 2025
|
PRIMARY | |||
|
D015041
Created by
admin on Mon Mar 31 18:26:21 GMT 2025 , Edited by admin on Mon Mar 31 18:26:21 GMT 2025
|
PRIMARY | |||
|
3311
Created by
admin on Mon Mar 31 18:26:21 GMT 2025 , Edited by admin on Mon Mar 31 18:26:21 GMT 2025
|
PRIMARY | |||
|
1535252
Created by
admin on Mon Mar 31 18:26:21 GMT 2025 , Edited by admin on Mon Mar 31 18:26:21 GMT 2025
|
PRIMARY | RxNorm | ||
|
31352-82-6
Created by
admin on Mon Mar 31 18:26:21 GMT 2025 , Edited by admin on Mon Mar 31 18:26:21 GMT 2025
|
PRIMARY | |||
|
Zolazepam
Created by
admin on Mon Mar 31 18:26:21 GMT 2025 , Edited by admin on Mon Mar 31 18:26:21 GMT 2025
|
PRIMARY | |||
|
m11657
Created by
admin on Mon Mar 31 18:26:21 GMT 2025 , Edited by admin on Mon Mar 31 18:26:21 GMT 2025
|
PRIMARY | Merck Index | ||
|
G1R474U58U
Created by
admin on Mon Mar 31 18:26:21 GMT 2025 , Edited by admin on Mon Mar 31 18:26:21 GMT 2025
|
PRIMARY | |||
|
100000078794
Created by
admin on Mon Mar 31 18:26:21 GMT 2025 , Edited by admin on Mon Mar 31 18:26:21 GMT 2025
|
PRIMARY | |||
|
SUB00175MIG
Created by
admin on Mon Mar 31 18:26:21 GMT 2025 , Edited by admin on Mon Mar 31 18:26:21 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |